The company markets its products through its sales representatives, distributors, and wholesalers, as well as through third party vendors. coli asparaginase hypersensitivity and Leukotac, an anti-CD25 monoclonal antibody is in Phase III clinical trials for the treatment of steroid-refractory acute graft vs.
Further, it develops Asparec, a pegylated recombinant Erwinia asparaginase that is in Phase I clinical trials for the treatment of patients with ALL with E. In addition, the company offers Collatamp, a surgical implant impregnated with the antibiotic gentamicin Fomepizole to treat ethylene glycol poisoning Kidrolase for treating ALL, Leukaemic meningitis, and non-Hodgkin's lymphoma Xenazine to treat movement disorders associated with Huntington's chorea and hemiballismus and Custodiol, a ready to use solution used in organ transplantation. It also provides Luvox CR to treat obsessive compulsive disorder Versacloz oral suspension Caphosol to treat oral mucositis Quadramet for the treatment of pain in patients whose cancer has spread to the bones ProstaScint for imaging the extent and spread of prostate cancer Niravam for the treatment of generalized anxiety and panic disorders and Parcopa for the symptoms associated with idiopathic Parkinson's disease treatment. The company's products include Xyrem for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy Erwinaze to treat acute lymphoblastic leukemia Prialt for the management of severe chronic pain and FazaClo LD and FazaClo HD, which are orally disintegrating clozapine tablets for the resistant schizophrenia treatment. To read this article on click here.Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries.
Yahoo finance stocks jazz pharmaceuticals free#
Jazz Pharmaceuticals PLC (JAZZ) : Free Stock Analysis Report
Yahoo finance stocks jazz pharmaceuticals download#
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. With strong valuation and earnings metrics, a good Zacks Rank, and top-tier Value and VGM Style Scores, investors should strongly think about adding JAZZ to their portfolios. JAZZ has an average earnings surprise of 10.9%. The Zacks Consensus Estimate has increased $0.00 to $17.35 per share.
One analyst revised their earnings estimate upwards in the last 60 days for fiscal 2022. Value investors don't just pay attention to a company's valuation ratios positive earnings play a crucial role, too. Value investors should also note JAZZ's Price/Sales ratio of 2.4X. Additionally, JAZZ has a PEG Ratio of 0.7 and a Price/Cash Flow ratio of 5.9X. Shares are currently trading at a forward P/E of 7.8X for the current fiscal year compared to the Medical - Drugs industry's P/E of 14.5X. JAZZ is a Zacks Rank #1 (Strong Buy) stock, with a Value Style Score of B and VGM Score of B. Xywav was also approved for treating idiopathic hypersomnia (IH). Both drugs are approved for treating cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients. Xywav is a low-sodium formulation of Jazz’s legacy drug, Xyrem, which was launched in 2020. The company derives the majority of its revenues from its sleep disorder drugs - Xywav and Xyrem.
Utilizing ratios like P/E, PEG, Price/Sales, and Price/Cash Flow, the Value Style Score identifies the most attractive and most discounted stocks.ĭublin, Ireland-based Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience and oncology. Value investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value.
0 kommentar(er)
